Prescription medication · Rapid-Acting Insulin
insulin glulisine
Also sold as Apidra. Apidra is used to improve blood sugar control in adults and children with diabetes.
Data updated 2026-05-15
- 9,944
- FDA reportsLightly reported
- 9
- InteractionsFew interactions
- $8.17
- Brand price (NADAC)
What the data shows
insulin glulisine (Apidra) is a prescription Rapid-Acting Insulin, reported less often than most tracked drugs (9,944 FDA reports), with 9 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
insulin glulisine (Apidra) is a prescription Rapid-Acting Insulin. Apidra is used to improve blood sugar control in adults and children with diabetes.
Apidra is a rapid-acting insulin that helps control blood sugar levels in people with diabetes. It works quickly to lower blood sugar after meals.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$8.17/unit
Generic Available
No
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Apidra is used to improve blood sugar control in adults and children with diabetes.
Common side effects
Upper respiratory infection, Nasopharyngitis (common cold), Hypoglycemia (low blood sugar)
Key warnings
Never share your Apidra SoloStar pen with anyone else, even if you change the needle.
The sections below are summarized in plain English from insulin glulisine's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Apidra is a type of insulin that works fast. It helps your body use sugar from the food you eat. This lowers the amount of sugar in your blood.
Side Effects (from patient reports)
Based on 9,944 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for insulin glulisine, by number of reports
- Blood Glucose Increased
Blood Glucose Increased
1,526 reports
- Hypoglycaemia
Hypoglycaemia
756 reports
- Hyperglycaemia
Hyperglycaemia
634 reports
- Blood Glucose Decreased 445
Blood Glucose Decreased
445 reports
- Dizziness 401
Dizziness
401 reports
- Malaise 392
Malaise
392 reports
- Dyspnoea 383
Dyspnoea
383 reports
- Nausea 370
Nausea
370 reports
- Vomiting 335
Vomiting
335 reports
- Acute Kidney Injury 304
Acute Kidney Injury
304 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for insulin glulisine each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where insulin glulisine sits
insulin glulisine has more FDA adverse-event reports than 39% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is insulin glulisine; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 9,944 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2005–2025.
Total Reports
9,944
Reports Mentioning Death
795
8.0% of reports — not proof of cause
Hospitalization Reports
4,001
Top Indication
Diabetes Mellitus
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | BLOOD GLUCOSE INCREASED | 1,526 |
| 2 | HYPOGLYCAEMIA | 756 |
| 3 | HYPERGLYCAEMIA | 634 |
| 5 | BLOOD GLUCOSE DECREASED | 445 |
| 6 | DIZZINESS | 401 |
| 7 | MALAISE | 392 |
| 8 | DYSPNOEA | 383 |
| 9 | NAUSEA | 370 |
| 10 | VOMITING | 335 |
| 11 | ACUTE KIDNEY INJURY | 304 |
| 12 | FATIGUE | 297 |
| 13 | ASTHENIA | 293 |
| 14 | DIARRHOEA | 279 |
| 15 | PAIN | 271 |
| 16 | FALL | 269 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Never share your Apidra SoloStar pen with anyone else, even if you change the needle. Sharing pens can spread blood-borne diseases. Changes in your insulin regimen should be made carefully under medical supervision because it can cause hyperglycemia or hypoglycemia. Low potassium levels in your blood can occur and may be life-threatening. Watch for signs of heart failure if you are also taking thiazolidinediones (TZDs).
Known Drug Interactions
7 DRUG INTERACTIONS Table 6: Clinically Significant Drug Interactions with APIDRA Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics.
Mechanism: Fluoxetine can increase the risk of low blood sugar when taken with insulin.
7 DRUG INTERACTIONS Table 6: Clinically Significant Drug Interactions with APIDRA Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics.
Mechanism: Pramlintide can increase the risk of low blood sugar when taken with insulin.
7 DRUG INTERACTIONS Table 6: Clinically Significant Drug Interactions with APIDRA Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics.
Mechanism: Octreotide can increase the risk of low blood sugar when taken with insulin.
Drugs that May Decrease the Blood Glucose Lowering Effect of APIDRA Drugs: Atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, phenothiazine derivatives, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.
Mechanism: Albuterol can cause blood sugar levels to rise, which counteracts the effect of the insulin.
Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of APIDRA Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. Drugs that May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine. ( 7 ) Antiadrenergic Drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine): Signs and symptoms of hypoglycemia may be reduced or absent.
Mechanism: Clonidine can change how insulin affects your blood sugar and can also hide the warning signs of low blood sugar.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What should I do if my blood sugar is too high?
Can I mix Apidra with other insulins?
How often should I check my blood sugar?
What are the symptoms of low blood sugar?
What should I do if I have low blood sugar?
Can other medicines affect Apidra?
What if my insulin pump malfunctions?
How long does Apidra last in my system?
Can I travel with Apidra?
What do I do with used needles?
What are the common side effects of insulin glulisine?
Does insulin glulisine interact with other medications?
What drug class is insulin glulisine?
What pregnancy or breastfeeding source fields are listed for insulin glulisine?
Related Medications in Rapid-Acting Insulin
Other drugs grouped near insulin glulisine - same-class peers and common alternatives.
acarbose
Precose
Acarbose is a medicine that helps lower blood sugar levels in people with type 2 diabetes.
Compare with insulin glulisine →
alogliptin
Nesina
Compare with insulin glulisine →
bromocriptine
Cycloset
Bromocriptine (Cycloset) is a medicine that acts like dopamine in your body.
Compare with insulin glulisine →
canagliflozin
Invokana
Invokana is a medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Compare with insulin glulisine →
colesevelam
Welchol
Colesevelam is a medicine that helps lower bad cholesterol (LDL-C) and control blood sugar in adults.
Compare with insulin glulisine →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for insulin glulisine: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 9,944.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 7.99%.
- pregabalin Δ 0.02 pts · 264,092 reports · Anticonvulsant / Nerve Pain Agent 8.01%death share
- saxagliptin Δ 0.04 pts · 8,141 reports · DPP-4 Inhibitor 7.96%death share
- quinapril Δ 0.05 pts · 6,775 reports · ACE Inhibitor 8.04%death share
- methotrexate Δ 0.07 pts · 410,053 reports · Disease-Modifying Antirheumatic Drug (DMARD) 7.93%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on insulin glulisine
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for insulin glulisine
The FDA label for insulin glulisine (sold under brand names such as Apidra) classifies it as a prescription-only medication in the Rapid-Acting Insulin class. Apidra is used to improve blood sugar control in adults and children with diabetes. Official labeling lists 6 commonly reported side effects, including Upper respiratory infection, Nasopharyngitis (common cold), Hypoglycemia (low blood sugar).
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 9,944 voluntary reports. The database also lists 9 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: November 25, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages